Quarterly report · Q1
4564.TEDINET S100OW16
Period2022-04-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 30
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥386m | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥93m | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥307m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥572m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥314m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥572m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥277m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥278m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥535m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥2.0bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥2.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.6bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥373m | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥705m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.5bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-1.44 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 79.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.6% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 29
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥55,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥101m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥380m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥9m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥215m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥386m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥55,000 |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | −¥206m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥107m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥96m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥87m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥33m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥6m |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥62,000 |
| jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥431m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥102m |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥93m |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | −¥464m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 313
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes payable | Prior1YearInstant | 136533000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 34133000 | JPY |
| Other cl | Prior1YearInstant | 24008000 | JPY |
| Other cl | CurrentQuarterInstant | 39837000 | JPY |
| Current liabilities | Prior1YearInstant | 604923000 | JPY |
| Current liabilities | CurrentQuarterInstant | 272930000 | JPY |
| Deferred tax liabilities | Prior1YearInstant | 338000 | JPY |
| Deferred tax liabilities | CurrentQuarterInstant | 324000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 99703000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 99992000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 100041000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 100316000 | JPY |
| Liabilities | Prior1YearInstant | 704965000 | JPY |
| Liabilities | CurrentQuarterInstant | 373247000 | JPY |
| Capital stock | Prior1YearInstant | 789114000 | JPY |
| Capital stock | CurrentQuarterInstant | 789114000 | JPY |
| Capital surplus | Prior1YearInstant | 24793617000 | JPY |
| Capital surplus | CurrentQuarterInstant | 24793617000 | JPY |
| Retained earnings | Prior1YearInstant | -23686179000 | JPY |
| Retained earnings | CurrentQuarterInstant | -23963978000 | JPY |
| Shareholders equity | Prior1YearInstant | 1896553000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 1618753000 | JPY |
| Subscription rights to shares | Prior1YearInstant | 83680000 | JPY |
| Subscription rights to shares | CurrentQuarterInstant | 50543000 | JPY |
| Net assets | Prior1YearInstant | 1980233000 | JPY |
| Net assets | CurrentQuarterInstant | 1669297000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 2685199000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 2042544000 | JPY |
| Business revenue | Prior1YTDDuration | 93183000 | JPY |
| Business revenue | CurrentYTDDuration | 385703000 | JPY |
| Cost of sales | Prior1YTDDuration | 76686000 | JPY |
| Cost of sales | CurrentYTDDuration | 339261000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 467843000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 233591000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 120170000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 120202000 | JPY |
| Business expenses | Prior1YTDDuration | 664700000 | JPY |
| Business expenses | CurrentYTDDuration | 693056000 | JPY |
| Operating income | Prior1YTDDuration | -571517000 | JPY |
| Operating income | CurrentYTDDuration | -307352000 | JPY |
| Interest income noi | Prior1YTDDuration | 63000 | JPY |
| Interest income noi | CurrentYTDDuration | － | JPY |
| Subsidy income noi bounty | Prior1YTDDuration | 389000 | JPY |
| Subsidy income noi bounty | CurrentYTDDuration | － | JPY |
| Other noi | Prior1YTDDuration | 0 | JPY |
| Other noi | CurrentYTDDuration | － | JPY |
| Non operating income | Prior1YTDDuration | 452000 | JPY |
| Non operating income | CurrentYTDDuration | － | JPY |
| Stock issuance cost noe | Prior1YTDDuration | 137000 | JPY |
| Stock issuance cost noe | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |